Allurion Completes Enrollment In Pivotal AUDACITY Trial For The Allurion Balloon
Portfolio Pulse from Benzinga Newsdesk
Allurion Technologies, Inc. (NYSE:ALUR) has completed patient enrollment in its AUDACITY trial, which is designed to support FDA approval of the Allurion Balloon, a novel weight loss device. The trial enrolled 550 patients at 17 sites and completed enrollment two months ahead of schedule. The Allurion Balloon is a swallowable, procedure-less gastric balloon for weight loss.
October 11, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Allurion's completion of patient enrollment for the AUDACITY trial brings the company one step closer to FDA approval of the Allurion Balloon. This could potentially open up a new market for the company in the United States.
The completion of patient enrollment for the AUDACITY trial is a significant milestone for Allurion. It indicates progress towards FDA approval of the Allurion Balloon, which could potentially open up a new market for the company in the United States. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100